StackWave

We want to express our gratitude to everyone who attended our presentation at this year: Software at Every Stage: Achieving Antibody Discovery at Scale. Your presence made it a tremendous success! 🙌

In case you missed it, no worries, you can catch the on-demand session on our website. 📺🔍 Simply visit https://bit.ly/48pMooq and dive into the world of antibody discovery at scale. 🧪🔬

Scientific Briefing - Software at Every Stage: Achieving Antibody Discovery at Scale
12/14 at 1:45pm PST
https://bit.ly/47WwSAo

With ever-larger amounts of data becoming central to the development of new medicines, it is critical to have the right systems in place to manage all of that data from the start. Spreadsheets, bespoke databases, and electronic laboratory notebooks all have shortcomings that can prevent teams from effectively and efficiently using their data. The best bioregistries are designed to properly model, record, and query biological data at scale, while also providing APIs to support integration and automation in the pursuit of FAIR data.

The Benefits of Bioregistry Software It has never been more important to organize, standardize, and centralize data collection in the pursuit of new medicines.

Phage display, a powerful technique for presenting peptides or proteins on bacteriophage surfaces, has revolutionized the discovery of therapeutic proteins. Developed by George P. Smith in 1985, this method enables high-throughput screening and selection of molecules with desired binding properties. To prepare a phage display library for nanobody discovery, animals like llamas or alpacas are immunized with the target antigen, triggering the production of heavy-chain-only antibodies. DNA fragments are then produced with the variable region domain sequences from these antibodies. These fragments are then cloned into phage display vectors, which are ultimately used to produce a diverse library of nanobodies displayed on the surface of phage particles.

https://bit.ly/3G69kgg

Harnessing Phage Display Libraries for the Discovery of Therapeutic Nanobodies Phage display has become an invaluable tool for the discovery of novel therapeutic agents, including nanobodies.

Top 5 issues that might occur during cDNA library preparation for NGS (and potential solutions):

1. Poor quality RNA
2. Inefficient reverse transcription
3. Low cDNA yield
4. Adapter dimer formation
5. Inconsistent fragment size

Troubleshooting Tips for cDNA Library Preparation in Next-Generation Sequencing Creating a cDNA library for next-generation sequencing (NGS) is a critical step in transcriptome studies.

Next-Generation Sequencing (NGS) has greatly impacted fields like genomics, transcriptomics, and immunology. Specifically, in nanobody discovery, NGS offers an efficient way to identify and extract variable domain heavy-chain (VHH) regions from camelid B-cells, eliminating the need for traditional methods. This article explores how NGS is used to identify antibodies of interest and extract the VHH region for nanobody expression, outlining the steps involved from immunization and B-cell isolation to library preparation, sequencing, and bioinformatics analysis.

Next-Generation Sequencing to Identify and Extract Nanobodies from Camelid B-cells NGS offers an approach for identifying and extracting variable domain heavy-chain (VHH) regions from camelid B-cells.

Nanobodies, derived from camelids like llamas and alpacas, are being explored as innovative strategies to combat viral and bacterial infections. These small and stable antibody fragments have shown promise in neutralizing viruses, such as SARS-CoV-2, by blocking the spike protein's interaction with human cells. Nanobodies can also target bacterial components, toxins, and even modulate the immune response. Overall, nanobody-based therapies offer a promising approach in the fight against infectious diseases.
https://bit.ly/3tTfmxY

Nanobodies in the Treatment of Viral and Bacterial Infections In the fight against infectious diseases, scientists are continually seeking to outsmart pathogens. One such strategy involves the use of nanobodies.

Scientists are investigating the potential of nanobodies, small single-domain antibodies derived from camelids, as a novel therapy for neurodegenerative diseases. Nanobodies offer benefits over traditional drugs and antibodies, with promising results in preclinical studies. Specifically, nanobodies targeting amyloid-beta in Alzheimer's disease have shown the ability to clear deposits and reduce inflammation. For Parkinson's disease, nanobodies targeting alpha-synuclein could prevent neuronal cell death. Additionally, nanobodies targeting mutant huntingtin in Huntington's disease have the potential to decrease toxicity and promote proper clearance. Overall, nanobodies hold promise as a therapeutic option for various brain diseases.

Nanobodies in Treating Neurodegenerative Diseases In the search for new therapies that can treat a wide variety of neurodegenerative diseases, scientists are exploring the potential of nanobodies.

Nanobodies, derived from heavy-chain-only antibodies found in camelids, are emerging as innovative therapeutic strategies for targeted cancer therapy. These small, single-domain antibody fragments exhibit unique properties like high stability, specificity, and small size. They have shown immense potential in targeting tumor-associated antigens thanks to their ability to resist denaturation and degradation in the tumor microenvironment. Nanobody mechanisms of action include targeting immune checkpoint proteins, inhibiting cancer cell growth, and inducing apoptosis. Nanobodies can also be engineered to deliver toxic payloads, selectively killing cancer cells while minimizing damage to healthy tissues.
https://bit.ly/3QiN6wd

Nanobodies, also known as VHHs or single-domain antibodies, are small, stable antibody fragments derived from heavy-chain-only antibodies found in camelids. They have been extensively studied for various applications, including diagnostics, imaging, and therapeutics. Belgian researchers discovered these unique antibodies in the early 1990s. Nanobodies possess attractive properties such as small size, high stability, specificity, low immunogenicity, and ease of engineering. They can access hard-to-reach targets, pe*****te dense tissues, and cross biological barriers. Nanobodies offer great potential as innovative therapeutic agents with a wide range of applications.
https://bit.ly/45E79e5

Bulk B cell analysis via next-generation sequencing (NGS) has revolutionized antibody discovery. This approach allows for comprehensive analysis of the antibody repertoire, identifying novel antibodies with therapeutic potential. In this blog post, we explore the process of bulk B cell analysis and its role in antibody discovery. By isolating and sequencing B cells, rare and unique antibody sequences can be identified. NGS analysis enables rapid identification of antibodies from a large population of B cells, making it a powerful tool in antibody discovery.
https://bit.ly/46Wmbgh

Bulk B Cell Analysis via NGS for Antibody Discovery Bulk B cell analysis is a powerful tool for antibody discovery because it provides a snapshot of the entire B cell population at a given time.